$XBI $129.81 -4%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Pipeline Updates
$CCXI -43% Adcom briefing docs released. source
$BLRX +52% Positive ph 3 GENESIS results of Motixafortide + G-CSF for multiple myeloma. source
$VXRT +4% First patient enrolled in ph1b Norovirus study. source
$SIGA +1% submits NDA for TIPOXX for smallpox. source
$CYTK -6% Ph 2 cohort 3 of REDWOOD-HCM open for enrollment. source
$CMPI -4% Initiated ph 2 combo study of Vido + Nivo. source
$OBSV +2% Completed enrollment for the Phase 3 EDELWEISS 3 trial of Yeslty® (linzagolix) for patients with moderate to severe endometriosis-associated pain (EAP). Data from the primary endpoint readout are expected in Q4 2021. source
Financial Updates
$COCP +52% $40M bought deal offering w/ HC Wainwright @ $1.54/sh. source
$ESPR -24% Revenue miss. source
$ATNX +20% to acquire Kuur Tx, terms include $70M upfront, and $115M of milestone payments, as cash or ATNX stock. source
$IBIO +27% settled lawsuit with Fraunhofer USA, IBIO receives payments and Fraunhofer USA license to use recombinant protein manufacturing technology. source
$PRQR -8% Yarrow bio in-licensed ASO tech to develop therapy for undisclosed target. source